Mission Statement, Vision, & Core Values of Zomedica Corp. (ZOM)

When you look at Zomedica Corp. (ZOM), the core mission-to enrich the lives of pets and enhance the economic health of veterinary practices-is the bedrock that explains the Q3 2025 revenue growth of $8.1 million, a 16% jump year-over-year. But how does a company with a $6.1 million net loss in the same quarter justify that mission as a sustainable investment thesis? Are the strategic moves, like the 51% growth in their Diagnostics segment, truly aligning with a long-term vision of profitability, or are they masking deeper operational challenges that need to be addressed before they burn through their $54.4 million in liquidity?

Zomedica Corp. (ZOM) Overview

Zomedica Corp. is a veterinary health company focused on delivering innovative, point-of-care diagnostic and therapeutic products for companion animals and horses. You should know they've built a business model around addressing the critical, unmet needs that clinical veterinarians face every day, so their products aren't just incremental improvements; they're designed to change the workflow.

The company, which was founded in 2013 and became publicly traded in 2015, operates out of Ann Arbor, Michigan. Their strategy has been to build and buy specialized technology, which is why their portfolio is diverse. It's a smart move to diversify revenue streams beyond a single product line.

• Diagnostic Solutions: The TRUFORMA platform uses Bulk Acoustic Wave (BAW) technology for precise, point-of-care diagnostics, plus the TRUVIEW digital cytology system and VETGuardian remote monitoring.
• Therapeutic Devices: This includes the PulseVet shock wave system for musculoskeletal disorders and the Assisi Loop line of targeted pulsed electromagnetic field (tPEMF) devices for pain and inflammation.
• New Revenue Stream: Their new Development Services segment captures revenue from providing engineering and contract manufacturing, even for companies in the human health sector.

For the third quarter of 2025, Zomedica Corp. reported a record quarterly revenue of $8.1 million, showing their strategy is defintely gaining traction in the market.

Q3 2025 Financial Performance: Breaking Down the Record Revenue

The latest financial reports for the period ended September 30, 2025, clearly show Zomedica Corp. is hitting a new gear. They posted their highest quarterly revenue ever at $8.1 million, an increase of 16% year-over-year, marking the 19th consecutive quarter of revenue growth. That kind of consistency is what I look for in a growing company.

The core of this growth is split between their diagnostic and therapeutic segments, but the recurring revenue from consumables is the real engine. Consumable sales, which include items like PulseVet trodes and TRUFORMA assay cartridges, grew by 14% year-over-year, reaching $5.4 million. This is a powerful sign of platform adoption and sustained use by veterinarians.

Here's the quick math on segment performance: The Diagnostics segment revenue, driven by accelerating TRUFORMA adoption, surged by 51% over the prior year quarter, contributing $0.7 million. The larger Therapeutic Device segment, featuring PulseVet and Assisi products, brought in $6.7 million, a solid 3% increase. Plus, the new Development Services segment added an initial $0.7 million. The company also maintained a strong gross margin of 67%.

To be fair, they still reported a net loss of $6.1 million, but that's a 9% improvement from the previous year, showing operational efficiencies are taking hold. They ended the quarter with a robust liquidity position of approximately $54.4 million in cash and equivalents, so they have plenty of runway to execute their growth plan.

Zomedica Corp. as a Veterinary Health Leader

In the veterinary health space, Zomedica Corp. is carving out a leadership position, especially in the niche of point-of-care solutions. They aren't trying to be a generalist; they are focused on high-value, specialized tools that directly impact a veterinarian's ability to diagnose and treat animals quickly and accurately.

Their international sales are also expanding, growing by 16% in Q3 2025, which demonstrates a successful global expansion strategy with new distribution partners in places like the UK, Netherlands, and Canada. This global reach, combined with strategic acquisitions like PulseVet, shows a clear path to becoming a dominant player in specialized animal healthcare.

The total addressable market for their recurring revenue products alone is estimated to be over $2.5 billion, with the capital sales market topping $1 billion, so the opportunity is significant. If you want to dive deeper into how these numbers translate to long-term value, you should check out Breaking Down Zomedica Corp. (ZOM) Financial Health: Key Insights for Investors. It will give you the full picture on why Zomedica Corp. is positioned for continued success.

Zomedica Corp. (ZOM) Mission Statement

You're looking for a clear map of where Zomedica Corp. is headed, and the mission statement is exactly that-the bedrock for every strategic decision, from R&D spending to commercial expansion. The company's mission is to advance the effectiveness and financial well-being of veterinary practitioners by delivering professionally beneficial products and services. This isn't just a feel-good phrase; it's a dual mandate that guides their product portfolio and their operational structure, and it's what we, as analysts, use to benchmark their execution.

A mission like this is crucial for a company operating in the competitive animal health sector. It forces alignment. For instance, the strategic move to achieve ISO 13485:2016 certification in November 2025, which is an internationally recognized quality standard for medical devices, directly supports the mission's product quality component. That kind of commitment is a tangible sign that they are serious about delivering on their promise.

If you want a deeper dive into the market's reception of this strategy, you should check out Exploring Zomedica Corp. (ZOM) Investor Profile: Who's Buying and Why?

Component 1: Advancing the Effectiveness of Veterinary Practitioners

The first core pillar is about making veterinarians better at their jobs. This means providing tools that offer better diagnostics, more precise therapeutics, and faster results. The company's focus on point-of-care (POC) solutions is the clearest expression of this goal. POC diagnostics, like the TRUFORMA platform, allow for immediate, accurate results, which translates directly into faster treatment and better patient outcomes.

The financial results from 2025 show this strategy is gaining traction. The Diagnostics segment, which includes TRUFORMA and TRUVIEW digital cytology, saw a significant growth of 51% in the third quarter of 2025, year-over-year. That's a powerful signal that veterinarians are adopting these innovative tools. Also, the therapeutic devices, like the PulseVet shock wave system, are considered a gold standard in accelerating healing for musculoskeletal conditions, defintely elevating the standard of care.

Here's the quick math on product impact:

• TRUFORMA Platform: Driving 51% Q3 2025 Diagnostics revenue growth.
• PulseVet System: A therapeutic device that transforms care for equine and companion animals.
• ISO 13485 Certification: Confirms a quality management system for medical devices, ensuring product reliability.

Component 2: Advancing the Financial Well-being of Veterinary Practitioners

It's not enough to have great products; they also have to make economic sense for the practice. Zomedica Corp. understands that the financial health of a veterinary clinic is directly tied to its ability to invest in new technology. So, their products are designed to create recurring, high-margin revenue streams for the practices themselves.

The proof is in the consumables. The company reported a 14% increase in consumable sales in Q3 2025. This is a crucial metric because it shows high utilization of their installed base-veterinarians aren't just buying the TRUFORMA platform; they are consistently buying the assay cartridges to run tests. Plus, Zomedica's own internal cost discipline, like the 2025 headquarters relocation that reduced base annual rent by over $200,000 annually, shows they value efficiency, which is a good proxy for how they manage the value proposition for their customers.

Component 3: Delivering Innovative, Unrivaled Products and Services

The third component is the mechanism: a commitment to innovation that yields a truly differentiated product suite. Zomedica Corp. is not just selling one-off equipment; they are building a portfolio of integrated solutions for both diagnostics and therapeutics across companion and equine health.

Their product line is diverse, covering a wide range of needs:

• Diagnostics: TRUFORMA (hormone and adrenal testing), TRUVIEW (digital cytology), and VETGuardian (no-touch monitoring).
• Therapeutics: PulseVet (shock wave therapy) and Assisi Loop (targeted pulsed electromagnetic field therapy).
• Surgical/Emergency: VETIGEL (hemostatic gel).

This comprehensive approach is why the company achieved record year-over-year revenue for the 19th straight quarter in Q3 2025, reaching $8.1 million. The gross margin of 67% in Q3 2025 further underscores the value and quality of these products. That's a strong margin, and it tells you they aren't competing on price alone; they're competing on superior technology and service.

Zomedica Corp. (ZOM) Vision Statement

You're looking for a clear map of Zomedica Corp.'s strategic direction, not just vague corporate speak. To be fair, Zomedica's vision isn't a single, flowery sentence; it's a concrete, two-pronged objective: to improve animal health and to enhance the economic health of veterinary practices. They know that one cannot succeed without the other.

This vision is a realist's take on the veterinary market. It recognizes that for a veterinarian to provide top-tier care, their practice must be financially sound. So, every product, from the TRUFORMA diagnostic platform to the PulseVet therapeutic system, must deliver on both the clinical outcome and the practice's bottom line.

Here's the quick math: In the third quarter of 2025, Zomedica posted a record revenue of $8.1 million, a 16% increase year-over-year, showing this dual focus is translating into sales. That revenue growth is the proof that vets are adopting solutions that truly help their workflow and cash flow.

Mission: Enriching Lives and Enhancing Practice Economics

The company's mission is the daily execution of that vision. It's about building, buying, and branding innovative products for unmet needs in the animal health community. This isn't just about selling a device; it's about delivering a comprehensive solution that makes a vet's life easier and a pet's life better.

The mission explicitly targets two key stakeholders: the animals we love and the veterinarians who care for them. For instance, the TRUFORMA platform allows for point-of-care diagnostics (testing right in the clinic), which means faster results for pets and a new, high-margin revenue stream for the practice. This is how they advance the effectiveness and financial well-being of practitioners.

You can see the full context of this strategy, including the history and how they make money, at Zomedica Corp. (ZOM): History, Ownership, Mission, How It Works & Makes Money.

Core Value 1: Innovation and Product Excellence

Innovation is not just a buzzword here; it's the engine driving their revenue, especially in diagnostics. The company's core value of innovation focuses on creating unrivaled products and services. For the third quarter of 2025, their Diagnostics segment-which includes TRUFORMA, TRUVIEW, and VETGuardian-grew an impressive 51% year-over-year.

This growth is fueled by continuous product expansion, like the addition of feline use to the Cobalamin and Folate assay on the TRUFORMA platform. Plus, they're not just relying on their own R&D; they've built a portfolio through strategic acquisitions to offer gold-standard systems like the PulseVet shock wave therapy.

• Accelerate product development.
• Secure new intellectual property (IP).
• Elevate veterinary care standards.

Core Value 2: Partnership and Collaboration

Honestly, you can't scale a specialized product portfolio without strong partners. Zomedica's value of collaboration is evident in its distribution strategy and its new Development Services segment. They've recently strengthened partnerships with distributors like Pioneer Veterinary Products in the United Kingdom and Grovet b.v. in the Netherlands, which is defintely crucial for international expansion.

What's interesting is the new Development Services revenue stream. This captures revenue from providing development and engineering services to other companies, including one in the human health space. In Q3 2025 alone, this new segment booked $0.7 million in revenue. This is a smart way to use their existing infrastructure and IP to generate planned operating leverage.

Core Value 3: Integrity and Financial Well-being

A company's financial health is a direct reflection of its operational integrity. While Zomedica is still working toward profitability-reporting a net loss of $6.1 million in Q3 2025-their focus is on maintaining a strong balance sheet to fund their growth. They ended the third quarter of 2025 with approximately $54 million in liquidity, which gives them a significant war chest for continued acquisitions and organic expansion.

The goal isn't just revenue; it's a high-quality revenue stream. Their gross margin stood at a strong 67% in Q3 2025, which is a key indicator of their ability to eventually reach self-sustaining operations. The commitment to financial well-being extends to their customers, aiming to improve the cash flow and profitability of veterinary practices through their products.

Zomedica Corp. (ZOM) Core Values

You're looking for a clear map of Zomedica Corp.'s operational priorities, and the best way to see that is through their core values, which are less about posters on a wall and more about where they put their cash and effort. Zomedica's mission is simple: advance animal health by giving veterinarians innovative therapeutic and diagnostic solutions. This mission drives three clear, actionable core values that shape their $8.1 million in Q3 2025 revenue and their future strategy.

To be fair, you won't find a standard list of five values, but their actions in 2025 speak louder than any corporate jargon. Here's how they translate their commitment to the vet community into concrete financial and operational results, which is what matters to investors like you. If you want a deeper dive into the shareholder base driving these results, check out Exploring Zomedica Corp. (ZOM) Investor Profile: Who's Buying and Why?

Innovation is the engine of any medical technology company, and Zomedica defintely treats it that way. This value is about consistently developing new, high-value products that solve real problems for veterinarians, not just incremental updates. It's a commitment measured in R&D dollars and intellectual property (IP) growth.

Here's the quick math: Zomedica spent $1.8 million on Research and Development (R&D) in the third quarter of 2025 alone, which is a substantial investment to build out their internal capabilities to develop and test next-generation products. This spending is directly tied to expanding their flagship platforms.

• Secured four additional U.S. patents in Q3 2025, extending their TRUFORMA assay capabilities and protecting the TRUVIEW microscope.
• Expanded the TRUFORMA diagnostic platform with new feline testing for cobalamin and folate, directly addressing a critical need in companion animal diagnostics.
• Launched the Assisi Loop Lounge, a scientifically backed therapeutic device, in October 2025, expanding their therapeutic device portfolio.

What this investment hides is the long-term potential of their new Development Services segment. This new revenue stream, which booked $0.7 million in Q3 2025 from work for a human health company, shows they are leveraging their IP and manufacturing infrastructure beyond the core vet market, a smart move for operating leverage.

This value means Zomedica doesn't just sell products; they aim to improve the workflow, cash flow, and profitability of veterinary practices. When vets succeed, Zomedica succeeds, so the focus is on point-of-care solutions that offer immediate, actionable results.

The financial results for Q3 2025 show this value in action. Total revenue grew 16% year-over-year to a record $8.1 million, driven by strong demand for their therapeutic devices like PulseVet and Assisi. More importantly, Diagnostics revenue, which is key to their recurring revenue model, increased by a massive 51% year-over-year, showing strong adoption of the TRUFORMA platform.

• Drove 51% year-over-year growth in the Diagnostics segment in Q3 2025, confirming the value proposition of the TRUFORMA system.
• Expanded international reach through a strategic distribution agreement with Pioneer Veterinary Products Limited in the UK during Q3 2025, broadening access to their innovative products in a key market.
• Achieved 14% growth in total consumable sales year-over-year, which is the ultimate indicator of customer satisfaction and repeat use of their diagnostic and therapeutic platforms.

It's about making the vet's life easier. The VetGuardian Zero Touch monitoring system, for example, is designed to empower veterinarians by reducing manual checks and improving patient care without adding complexity.

You can't deliver innovative, reliable diagnostic and therapeutic products without a deep commitment to operational excellence and quality management. This value is the backbone of their business, ensuring everything from manufacturing to distribution is world-class. It's about being precise and efficient.

Their gross margin remaining strong at 67% in Q3 2025 is a clear sign of tight operational control and effective supply chain management. This efficiency allows them to maintain a strong liquidity position, ending Q3 2025 with $54.4 million in cash, cash equivalents, and available-for-sale securities.

• Achieved ISO 13485 Certification in October 2025, which is the global standard for a quality management system in the medical device industry, underscoring a strengthened quality infrastructure.
• Reduced total operating expenses by $0.5 million sequentially to $12.0 million in Q3 2025, demonstrating effective cost management and a path toward profitability.
• Manufactures and distributes products from world-class facilities in Georgia and Minnesota, supporting their approximately 150 employees and ensuring supply chain reliability.

The ISO certification is a big deal, honestly. It tells you their quality control isn't just a suggestion; it's a verified, audited system that gives vets confidence in the diagnostic results and therapeutic performance of their devices.